Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

John M. McLaughlin(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Raúl Istúriz(Pfizer (United States)), Paula Peyrani(University of Louisville), Julio A. Ramírez(Norton Healthcare), Bradford D. Gessner(Pfizer (United States)), William A. Mattingly(University of Louisville), Heather L. Sings(Pfizer (United States)), Ruth Carrico(University of Louisville), David L. Swerdlow(Pfizer (United States)), Qin Jiang(Pfizer (United States)), Timothy L. Wiemken(University of Louisville)
Clinical Infectious Diseases
April 12, 2018
10.1093/cid/ciy312
Cited by 160

Related Papers

The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
|The Lancet|2017|2.4k
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
H1N1 2009 influenza virus infection during pregnancy in the USA
|The Lancet|2009|1.4k